Pantop%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion. ## Primary Indications * Gastroesophageal reflux disease (GERD) - symptomatic relief and healing of erosive esophagitis. * H. pylori eradication (in combination with antibiotics). * Zollinger-Ellison syndrome and other conditions of gastric hypersecretory states. * Prevention of NSAID-induced gastric ulcers. ## Adult Dosing * **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily for 4 to 8 weeks. Maintenance therapy may be 20-40 mg once daily. * **H. pylori Eradication:** 40 mg orally twice daily for 7 to 14 days in combination with specific antibiotics (e.g., amoxicillin and clarithromycin). * **Zollinger-Ellison Syndrome:** Starting dose typically 40 mg orally or intravenously once daily, titrate as needed. Doses up to 240 mg daily have been administered (divided doses may be required). * **Prevention of NSAID-induced ulcers:** 20-40 mg orally once daily. ## Pediatric Dosing Dosing varies significantly by indication and age. * **GERD (1 to 5 years):** 10 mg orally once daily. * **GERD (5 to 16 years):** 20 mg orally once daily. * **Erosive Esophagitis (5 to 16 years):** 20-40 mg orally once daily. * *Note: Higher doses may be used in specific clinical situations, but evidence is more limited. Consult specific pediatric guidelines.* ## Dose Adjustments No dose adjustment is typically required for hepatic impairment, although caution is advised and the lowest effective dose should be used. No dose adjustment is typically required for renal impairment. ## Contraindications * Known hypersensitivity to pantoprazole, other PPIs, or any component of the formulation. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use of PPIs has been associated with increased risk of: * Fractures (hip, wrist, spine) * Clostridium difficile infection * Vitamin B12 deficiency * Hypomagnesemia * Rebound acid hypersecretion upon discontinuation ## Key Drug Interactions * **Clopidogrel:** Pantoprazole may decrease the antiplatelet effect of clopidogrel. Avoid concurrent use if possible, or monitor closely. * **Ketoconazole, Itraconazole, Posaconazole, and other pH-dependent absorption drugs:** Pantoprazole can decrease absorption. * **Methotrexate:** PPIs may increase methotrexate levels. * **CYP2C19 substrates:** Monitor for altered levels of drugs metabolized by CYP2C19. ## Monitoring * Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, arrhythmias). * Monitor for signs of C. difficile infection (e.g., severe diarrhea). * Monitor bone mineral density with long-term therapy, especially in patients at risk for osteoporosis. * Monitor B12 levels with prolonged therapy. ## Clinical Pearls * Administer oral pantoprazole 30 minutes before a meal. * For intravenous administration, reconstitute and further dilute as per manufacturer instructions. * Discontinuation should ideally be tapered to avoid rebound acid hypersecretion. *** *This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines before making clinical decisions.*